These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 28394806)

  • 1. Immunogenicity of Pertussis Booster Vaccination in Children and Adolescents with Inflammatory Bowel Disease: A Controlled Study.
    Banaszkiewicz A; Gawronska A; Klincewicz B; Kofla-Dłubacz A; Grzybowska-Chlebowczyk U; Toporowska-Kowalska E; Malecka I; Stryczynska-Kazubska J; Feleszko W; Lazowska-Przeorek I; Karolewska-Bochenek K; Walkowiak J; Slusarczyk J; Radzikowski A; Demkow U; Albrecht P
    Inflamm Bowel Dis; 2017 May; 23(5):847-852. PubMed ID: 28394806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Immunosuppression Impairs Immunogenicity to Tetanus and Pertussis Vaccination Among Patients with Inflammatory Bowel Disease.
    Dezfoli S; Horton HA; Thepyasuwan N; Berel D; Targan SR; Vasiliauskas EA; Dubinsky M; Shih DQ; Kaur M; McGovern DP; Ippoliti A; Feldman EJ; Melmed GY
    Inflamm Bowel Dis; 2015 Aug; 21(8):1754-60. PubMed ID: 25985242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Pediatric Patients with Inflammatory Bowel Disease.
    Banaszkiewicz A; Targońska B; Kowalska-Duplaga K; Karolewska-Bochenek K; Sieczkowska A; Gawrońska A; Grzybowska-Chlebowczyk U; Krzesiek E; Łazowska-Przeorek I; Kotowska M; Sienkiewicz E; Walkowiak J; Gregorek H; Radzikowski A; Albrecht P
    Inflamm Bowel Dis; 2015 Jul; 21(7):1607-14. PubMed ID: 25919976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients.
    Caldera F; Saha S; Wald A; Garmoe CA; McCrone S; Megna B; Ley D; Reichelderfer M; Hayney MS
    Dig Dis Sci; 2018 Jun; 63(6):1532-1540. PubMed ID: 29594970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Song LY; Fenton T; Nachman SA; Levin MJ; Rosenblatt HM; Pelton SI; Borkowsky W; Edwards KM; Peters J;
    Pediatrics; 2007 Nov; 120(5):e1190-202. PubMed ID: 17938165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection.
    Barkoff AM; Gröndahl-Yli-Hannuksela K; Vuononvirta J; Mertsola J; Kallonen T; He Q
    Vaccine; 2012 Nov; 30(48):6897-902. PubMed ID: 22981763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial.
    Matsumoto H; Ohfuji S; Watanabe K; Yamagami H; Fukushima W; Maeda K; Kamata N; Sogawa M; Shiba M; Tanigawa T; Tominaga K; Watanabe T; Fujiwara Y; Hirota Y; Arakawa T
    J Gastroenterol; 2015 Aug; 50(8):876-86. PubMed ID: 25672513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years.
    Carlsson RM; Gustafsson L; Hallander HO; Ljungman M; Olin P; Gothefors L; Nilsson L; Netterlid E
    Vaccine; 2015 Jul; 33(31):3717-25. PubMed ID: 26057135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age.
    Langue J; Matisse N; Pacoret P; Undreiner F; Boisnard F; Soubeyrand B;
    Vaccine; 2004 Mar; 22(11-12):1406-14. PubMed ID: 15063563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis.
    Cleveland NK; Rodriquez D; Wichman A; Pan I; Melmed GY; Rubin DT
    Dig Dis Sci; 2016 Oct; 61(10):2972-2976. PubMed ID: 27557706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster.
    Mallet E; Matisse N; Mathieu N; Langue J; Boisnard F; Soubeyrand B;
    Vaccine; 2004 Mar; 22(11-12):1415-22. PubMed ID: 15063564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium.
    Vandermeulen C; Theeten H; Rathi N; Kuriyakose S; Han HH; Sokal E; Hoppenbrouwers K; Van Damme P
    Vaccine; 2015 Jun; 33(26):3026-34. PubMed ID: 25613716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
    Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
    Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab.
    Moses J; Alkhouri N; Shannon A; Raig K; Lopez R; Danziger-Isakov L; Feldstein AE; Zein NN; Wyllie R; Carter-Kent C
    Am J Gastroenterol; 2012 Jan; 107(1):133-8. PubMed ID: 21876562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diphtheria, tetanus and pertussis antibodies in 10-year-old children before and after a booster dose of three toxoids: implications for the timing of a booster dose.
    Trollfors B; Knutsson N; Taranger J; Mark A; Bergfors E; Sundh V; Lagergård T
    Eur J Pediatr; 2006 Jan; 165(1):14-8. PubMed ID: 16249929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease.
    deBruyn JC; Hilsden R; Fonseca K; Russell ML; Kaplan GG; Vanderkooi O; Wrobel I
    Inflamm Bowel Dis; 2012 Jan; 18(1):25-33. PubMed ID: 21472826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
    Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
    Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents.
    Huang LM; Chang LY; Tang H; Bock HL; Lu CY; Huang FY; Lin TY; Lee CY
    J Adolesc Health; 2005 Dec; 37(6):517. PubMed ID: 16310132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunity to pertussis 5 years after booster immunization during adolescence.
    Edelman K; He Q; Mäkinen J; Sahlberg A; Haanperä M; Schuerman L; Wolter J; Mertsola J
    Clin Infect Dis; 2007 May; 44(10):1271-7. PubMed ID: 17443462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.